Loading...
•
Jun 30, 2023
Collegium Q2 2023 Earnings Report
Collegium reported strong financial results for Q2 2023, marked by double-digit revenue growth and disciplined expense management.
Key Takeaways
Collegium Pharmaceutical, Inc. reported a net revenue of $135.5 million for Q2 2023, a 10% increase year-over-year. GAAP net income was $13.0 million, with adjusted EBITDA reaching $85.8 million, up 21% year-over-year.
Net Revenue for Q2 2023 was $135.5 million, up 10% year-over-year.
GAAP Net Income for Q2 2023 was $13.0 million.
Adjusted EBITDA for Q2 2023 was $85.8 million, up 21% year-over-year.
The Board of Directors authorized a $50 million Accelerated Share Repurchase program.
Revenue by Segment
Forward Guidance
The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...